CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Oncology to Participate in Upcoming Investor Conferences

30 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

06 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

10 8 2023 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

09 8 2023 07:00:51 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

31 7 2023 08:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

25 5 2023 17:00:26 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

11 5 2023 16:01:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

26 4 2023 10:08:32 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

20 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

27 3 2023 07:00:06 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

14 3 2023 16:35:18 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

09 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

27 2 2023 08:00:02 提供 Nasdaq GlobeNewswire

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

13 2 2023 19:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

02 2 2023 16:01:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 2 2023 16:41:55 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

24 1 2023 08:00:02 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 1 2023 17:13:42 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 12 2022 17:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

14 11 2022 07:00:03 提供 Nasdaq GlobeNewswire